US$ 26.97
glp 1 agonist fda approval Lilly is now pharma's top revenue company. It just got for an oral GLP-1, but Wall Street isn't celebrating Trends in the Development of
Description
Similarly, patients with Parkinsons disease showed an improvement in motor parameters according to the criteria of the Movement Disorders Society Unified Parkinsons Disease Rating Scale (MDS-UPDRS) after treatment with exenatide [25, 26]

doi: 10.3390/biom10010040 42 NyakasCGranicIHalmyLGBanerjeePLuitenPG

verified that GLP-1RAs alleviate inflammation and peripheral nerve dysfunction through p38 MAPK/NF-B signaling pathways [75]

PMID 24112036
